Showing 1,121 - 1,140 results of 23,606 for search '(( 5 ((wt decrease) OR (nn decrease)) ) OR ( 100 ((we decrease) OR (a decrease)) ))', query time: 0.92s Refine Results
  1. 1121
  2. 1122
  3. 1123

    Memantine decreases the level of activated GSK-3β and the expression of intraneuronal Aβ. by Xiaochuan Wang (550306)

    Published 2016
    “…<p>A) While the level of total GSK-3β was not changed, pSer-9 GSK-3β was markedly decreased in AAV1-I<sub>1</sub><sup>PP2A</sup> as compared with the AAV1-GFP rats in hippocampus, cerebral cortex and ventricular areas. …”
  4. 1124
  5. 1125

    A brief course of RAP treatment decreases markers of proliferation and increases markers of differentiation. by Karin M. Hardiman (555189)

    Published 2014
    “…(E) Immunostaining shows increased Sox9 (a cell fate marker) expression in polyps and RAP decreased the number of cells expressing Sox9. …”
  6. 1126
  7. 1127
  8. 1128
  9. 1129
  10. 1130
  11. 1131

    The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study by Andrew S. Azman (121645)

    Published 2015
    “…Using our best estimates of one- and two-dose efficacy, we projected that a single-dose reactive campaign could have prevented 70,584 (95% prediction interval [PI] 55,943–86,205) cases in Zimbabwe, 78,317 (95% PI 57,435–100,150) in Port-au-Prince, Haiti, and 2,826 (95% PI 2,490–3,170) cases in Conakry, Guinea: 1.1 to 1.2 times as many as a two-dose campaign. …”
  12. 1132

    Effect of Adalimumab on Peripheral Blood Mononuclear Cells in Non-Infectious Uveitis by Karoline Walscheid (4507540)

    Published 2017
    “…</p> <p><i>Methods:</i> PBMCs and serum S100A12 levels from 14 uveitis patients and 28 healthy controls were analyzed. …”
  13. 1133
  14. 1134
  15. 1135
  16. 1136
  17. 1137

    β-catenin shRNA alters the migration and invasion of PDAC cells in vitro. by Xue Chen (127892)

    Published 2015
    “…<p>(A) The wound-healing assay revealed a significant decrease in migration in the β-catenin shRNA group (left), relative to the control group (right). …”
  18. 1138
  19. 1139
  20. 1140